MedTrace Logo

SPG Block for Acute Pediatric Migraine

NCT03984045 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2021-11-17

No results posted yet for this study

Summary

This is a randomized double blind trial comparing an intranasal sphenopalatine block with 2% lidocaine to intravenous (0.15 mg/kg, max 10mg) prochlorperazine in patients greater than 10 years of age presenting to a pediatric emergency department with an acute frontal migraine headache.

Conditions

  • Migraine in Children
  • Sphenopalatine Neuralgia
  • Migraine in Adolescence

Interventions

DRUG

Lidocaine topical

Intranasal 2% lidocaine delivered directly to SPG

DRUG

Prochlorperazine Injection

intravenous prochlorperazine at 0.15mg/kg max 10 mg

Sponsors & Collaborators

  • Newark Beth Israel Medical Center

    lead OTHER

Principal Investigators

  • Adam Sivitz, MD · Newark Beth Israel Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Max Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-06
Primary Completion
2022-06-30
Completion
2022-12-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03984045 on ClinicalTrials.gov